Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

SHOCKING: This dividend powerhouse is heading into q3 earnings with plenty at stake - You Need To See This

AbbVie (ABBV) has built a multibillion-dollar drug empire, steadily boosted its dividend, and developed a new generation of blockbuster medicines, making it a favorite among income-oriented investors.

The pharmaceutical giant is slated to report its third quarter results on Oct. 30, and expectations are running high. Investors are keen to see whether AbbVie's new medicines can deliver the earnings needed to sustain its remarkable 54-year dividend-growth streak, especially after Humira’s decline.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.